Basilea Pharmaceutica AG Stock OTC Markets
Equities
BPMUF
CH0011432447
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
48.15 USD | +8.32% | 0.00% | +17.44% |
Sales 2024 * | 182M 199M 272M | Sales 2025 * | 206M 225M 307M | Capitalization | 535M 586M 799M |
---|---|---|---|---|---|
Net income 2024 * | 23M 25.21M 34.38M | Net income 2025 * | 35M 38.36M 52.32M | EV / Sales 2024 * | 3.26 x |
Net Debt 2024 * | 57.88M 63.45M 86.52M | Net Debt 2025 * | 12.51M 13.71M 18.7M | EV / Sales 2025 * | 2.66 x |
P/E ratio 2024 * |
22.2
x | P/E ratio 2025 * |
18.7
x | Employees | 147 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.61% |
Latest transcript on Basilea Pharmaceutica AG
1 day | +8.32% | ||
Current month | +8.32% | ||
1 month | +8.32% | ||
3 months | +18.16% | ||
6 months | +17.44% | ||
Current year | +17.44% |
Managers | Title | Age | Since |
---|---|---|---|
David Veitch
CEO | Chief Executive Officer | 59 | 14-08-31 |
Adesh Kaul
DFI | Director of Finance/CFO | 50 | 08-12-31 |
Gerrit Hauck
CTO | Chief Tech/Sci/R&D Officer | 60 | 18-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Nicole Onetto
BRD | Director/Board Member | 71 | 17-04-26 |
Leonard Kruimer
BRD | Director/Board Member | 66 | 21-12-31 |
Director/Board Member | 69 | 13-04-08 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+54.05% | 63.85B | |
-2.02% | 41.83B | |
+40.01% | 40.47B | |
-10.22% | 27.17B | |
+13.42% | 26.52B | |
-21.60% | 18.69B | |
+2.89% | 12.73B | |
+22.40% | 12.11B | |
+27.49% | 12.07B |
- Stock Market
- Equities
- BSLN Stock
- BPMUF Stock